Anatabine is primarily researched for its potential neuroprotective and anti-inflammatory properties. It has been investigated in the context of neurological disorders such as Alzheimer’s disease, where it may help reduce the accumulation of amyloid-beta plaques and modulate neuroinflammation. Anatabine also shows promise in supporting cognitive function by influencing nicotinic acetylcholine receptor activity, though with less binding affinity than nicotine, which may result in a more favorable safety profile.

It has been explored as a dietary supplement ingredient aimed at promoting brain health and reducing inflammation. Some studies suggest anatabine may also have applications in reducing symptoms associated with autoimmune conditions and chronic inflammatory diseases. However, clinical evidence remains limited, and further research is needed to confirm its efficacy and long-term safety in humans.